Cutaneous rash as a surrogate marker of time to tumor progression (TTP) with erlotinib in previously treated advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Cedres Perez, S. [1 ]
Prat, A. [1 ]
Felip, E. [1 ]
Peralta, S. [1 ]
Perez, J. [1 ]
del Campo, J. [1 ]
Sala, G. [1 ]
Andreu, J. [1 ]
Pallisa, E. [1 ]
Baselga, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19125
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer
    Clement-Duchene, Christelle
    Natale, Ronald B.
    Jahan, Thierry
    Krupitskaya, Yelena
    Osarogiagbon, Raymond
    Sanborn, Rachel E.
    Bernstein, Eric D.
    Dudek, Arkadiusz Z.
    Latz, Jane E.
    Shi, Peipei
    Wakelee, Heather A.
    LUNG CANCER, 2012, 78 (01) : 57 - 62
  • [32] Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer
    Blair, Hannah A.
    TARGETED ONCOLOGY, 2018, 13 (03) : 399 - 407
  • [33] Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer
    Hannah A. Blair
    Targeted Oncology, 2018, 13 : 399 - 407
  • [34] PHASE II TRIAL OF ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Okano, Yoshio
    Shinohara, Tsutomu
    Machida, Hisanori
    Hatakeyama, Nobuo
    Takeuchi, Eiji
    Doi, Hiroyuki
    Kubota, Tetsuya
    Yokoyama, Akihito
    Ogushi, Fumitaka
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1175 - S1176
  • [35] Sunitinib in Combination with Erlotinib for the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Thongprasert, Sumitra
    Govindan, Ramaswamy
    Krzakowski, Maciej
    Szczesna, Aleksandra
    Strausz, Janos
    Makhson, Anatoly
    Tye, Lesley
    Zhang, Ke
    Chao, Richard C.
    Scagliotti, Giorgio V.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S375 - S375
  • [36] Erlotinib (Tarceva) for advanced non-small cell lung cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2005, 47 (1205): : 25 - 26
  • [37] Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
    Guttman-Yassky, Emma
    Mita, Alain
    De Jong, Maja
    Matthews, Lesley
    McCarthy, Sean
    Iwata, Kenneth K.
    Verweij, Jaap
    Rowinsky, Eric K.
    Krueger, James G.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) : 2010 - 2019
  • [38] Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
    Jacopo Giuliani
    Marina Marzola
    Archives of Dermatological Research, 2013, 305 : 653 - 658
  • [39] Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)
    Tiseo, Marcello
    Andreoli, Roberta
    Gelsomino, Francesco
    Mozzoni, Paola
    Azzoni, Cinzia
    Bartolotti, Marco
    Bortesi, Beatrice
    Goldoni, Matteo
    Silini, Enrico Maria
    De Palma, Giuseppe
    Mutti, Antonio
    Ardizzoni, Andrea
    LUNG CANCER, 2014, 83 (02) : 265 - 271
  • [40] Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
    Giuliani, Jacopo
    Marzola, Marina
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2013, 305 (07) : 653 - 658
12345